Clinical TrialsAstraZeneca and HUTCHMED Report Positive SAFFRON Phase III Results in MET-D... AstraZeneca and HUTCHMED Report Positive SAFFRON Phase III Results in MET-D... Read Post »
ResearchLong-Acting Broadly Neutralising Antibodies Delay HIV Viral Rebound After A... Long-Acting Broadly Neutralising Antibodies Delay HIV Viral Rebound After A... Read Post »
New Drug ApprovalFDA Approves TAUKLARIFY, Expanding Tau PET Imaging for Alzheimer’s Diseas... FDA Approves TAUKLARIFY, Expanding Tau PET Imaging for Alzheimer’s Diseas... Read Post »
Clinical TrialsSecukinumab Nearly Doubles Sustained Remission in Relapsed Polymyalgia Rheu... Secukinumab Nearly Doubles Sustained Remission in Relapsed Polymyalgia Rheu... Read Post »
Clinical TrialsArkBio’s Ziresovir Advances Into FDA-Cleared Phase II Trial in Critically... ArkBio’s Ziresovir Advances Into FDA-Cleared Phase II Trial in Critically... Read Post »
Medical DevicesFDA Clears Galaxy Buds for Adults With Mild to Moderate Hearing Loss FDA Clears Galaxy Buds for Adults With Mild to Moderate Hearing Loss Read Post »
Health TidingsCaribou Reports Mature CAR-T Trials Results for Vispa-cel in LBCL and CB-01... Caribou Reports Mature CAR-T Trials Results for Vispa-cel in LBCL and CB-01... Read Post »
New Drug ApprovalBMS’s ZENBEXUS Becomes First FDA-Approved CELMoD for RRMM BMS’s ZENBEXUS Becomes First FDA-Approved CELMoD for RRMM Read Post »
Mergers & AcquisitionsZealand Pharma Sells Rusfertide Royalty Rights to Royalty Pharma for $100 M... Zealand Pharma Sells Rusfertide Royalty Rights to Royalty Pharma for $100 M... Read Post »
New Drug ApprovalChina Approves Ivonescimab Combination for First-Line Squamous NSCLC China Approves Ivonescimab Combination for First-Line Squamous NSCLC Read Post »
Health TidingsTHPharm Bets on Reverse Drug Development, Linking Drug Effects to New Disea... THPharm Bets on Reverse Drug Development, Linking Drug Effects to New Disea... Read Post »
Clinical TrialsClearmind Advances CMND-100 Trial into AUD After Positive Safety Review Clearmind Advances CMND-100 Trial into AUD After Positive Safety Review Read Post »
Health TidingsLilly Escalates Legal Action Against U.S. Sellers of Unapproved Retatrutide Lilly Escalates Legal Action Against U.S. Sellers of Unapproved Retatrutide Read Post »
Clinical TrialsINGREZZA Improves Quality of Life and Daily Functioning in Phase 4 Tardive ... INGREZZA Improves Quality of Life and Daily Functioning in Phase 4 Tardive ... Read Post »
Clinical TrialsLecanemab in the Real World: Duke Study Reveals How Alzheimer’s Therapy P... Lecanemab in the Real World: Duke Study Reveals How Alzheimer’s Therapy P... Read Post »
Health TidingsNatera and Kupando Collaborate on Phase 1 Trial of KUP-101 Using Latitude t... Natera and Kupando Collaborate on Phase 1 Trial of KUP-101 Using Latitude t... Read Post »
Health TidingsSagimet Receives FDA Clearance to Advance Phase 3 Denifanstat Acne Trial Sagimet Receives FDA Clearance to Advance Phase 3 Denifanstat Acne Trial Read Post »
Health TidingsRemepy Advances Hybridopa Toward Phase III After Positive Parkinson’s Dis... Remepy Advances Hybridopa Toward Phase III After Positive Parkinson’s Dis... Read Post »
Clinical TrialsNeOnc Reports 48.9% Six-Month PFS With NEO100 in IDH1-Mutant Glioma NeOnc Reports 48.9% Six-Month PFS With NEO100 in IDH1-Mutant Glioma Read Post »
Health TidingsAttralus’ Zamubafusp Alfa Gets FDA Fast Track for AL Amyloidosis Attralus’ Zamubafusp Alfa Gets FDA Fast Track for AL Amyloidosis Read Post »
Health TidingsCan-Fite Advances Namodenoson in Liver Cancer and Piclidenoson in Psoriasis Can-Fite Advances Namodenoson in Liver Cancer and Piclidenoson in Psoriasis Read Post »
Clinical TrialsREZILIENT3 Trial Shows PFS Benefit With Zipalertinib Plus Chemotherapy in N... REZILIENT3 Trial Shows PFS Benefit With Zipalertinib Plus Chemotherapy in N... Read Post »
Clinical TrialsLeap’s Sirexatamab Misses PFS Endpoint in mCRC but Shows Greater Benefit ... Leap’s Sirexatamab Misses PFS Endpoint in mCRC but Shows Greater Benefit ... Read Post »
Health TidingsDefinium’s DT120 Meets All Key Endpoints in Phase 3 Voyage Trial for Gene... Definium’s DT120 Meets All Key Endpoints in Phase 3 Voyage Trial for Gene... Read Post »
Health TidingsAnnexon Adds Month 24 Endpoint to Phase 3 ARCHER II Trial of Vonaprument in... Annexon Adds Month 24 Endpoint to Phase 3 ARCHER II Trial of Vonaprument in... Read Post »
Health TidingsBelite Bio’s Tinlarebant Wins FDA Priority Review for Stargardt Disease Belite Bio’s Tinlarebant Wins FDA Priority Review for Stargardt Disease Read Post »
New Drug ApprovalUK Becomes First European Country to Authorise Orforglipron UK Becomes First European Country to Authorise Orforglipron Read Post »
New Drug ApprovalEnhertu® Plus Pertuzumab Approved in China as First-Line Treatment for HER... Enhertu® Plus Pertuzumab Approved in China as First-Line Treatment for HER... Read Post »
Health TidingsPDS Biotech Shifts Focus to PDS0301, Discontinues PDS0101 Phase 3 Program PDS Biotech Shifts Focus to PDS0301, Discontinues PDS0101 Phase 3 Program Read Post »
Clinical TrialsBEL512 Shows Positive Phase 2 Results in CRSwNP, Supporting Potential for S... BEL512 Shows Positive Phase 2 Results in CRSwNP, Supporting Potential for S... Read Post »
Health TidingsFDA Accepts Lonafarnib NDA for Chronic Hepatitis D, Advancing Potential Fir... FDA Accepts Lonafarnib NDA for Chronic Hepatitis D, Advancing Potential Fir... Read Post »
Clinical TrialsJW Pharmaceutical’s Epaminurad 6 mg Shows Superiority Over Febuxostat... JW Pharmaceutical’s Epaminurad 6 mg Shows Superiority Over Febuxostat... Read Post »
Health Tidings Mergers & AcquisitionsSentynl Secures U.S. Option for Mereo’s Alvelestat Ahead of Phase 3 in AA... Sentynl Secures U.S. Option for Mereo’s Alvelestat Ahead of Phase 3 in AA... Read Post »
ResearchAfter 10-Year Clinical Outcomes, Penn Medicine Study Finds CD19 CAR T Cells... After 10-Year Clinical Outcomes, Penn Medicine Study Finds CD19 CAR T Cells... Read Post »
Health TidingsObinutuzumab β Reduces Relapse Risk by 93.1% in Phase 3 Trial of AQP4-IgG-... Obinutuzumab β Reduces Relapse Risk by 93.1% in Phase 3 Trial of AQP4-IgG-... Read Post »
Mergers & AcquisitionsJazz Pharmaceuticals to Acquire Actio Biosciences to Expand Rare Epilepsy P... Jazz Pharmaceuticals to Acquire Actio Biosciences to Expand Rare Epilepsy P... Read Post »
Health TidingsFDA Grants Fast Track Designation to AC Immune’s ACI-7104 for Parkinson D... FDA Grants Fast Track Designation to AC Immune’s ACI-7104 for Parkinson D... Read Post »
Clinical TrialsShattuck’s SL-325 Advances to Phase 2b in Crohn’s Disease with Durable ... Shattuck’s SL-325 Advances to Phase 2b in Crohn’s Disease with Durable ... Read Post »
Health TidingsVaderis Launches Phase 3 Trial of Engasertib in HHT After $152 Million Fund... Vaderis Launches Phase 3 Trial of Engasertib in HHT After $152 Million Fund... Read Post »
Clinical TrialsLZ901 Shows Strong Protection Against Herpes Zoster in Phase III Trial LZ901 Shows Strong Protection Against Herpes Zoster in Phase III Trial Read Post »
Health TidingsFDA Rejects ITM-11 NDA Over CMC and Facility Issues FDA Rejects ITM-11 NDA Over CMC and Facility Issues Read Post »
Clinical TrialsSilence’s Divesiran Meets Phase 2 Trial Endpoint in Polycythemia Vera Silence’s Divesiran Meets Phase 2 Trial Endpoint in Polycythemia Vera Read Post »
Health TidingsSoligenix Discontinues HyBryte Development After Phase 3 FLASH2 Trial Halte... Soligenix Discontinues HyBryte Development After Phase 3 FLASH2 Trial Halte... Read Post »
Health TidingsAquestive Reports Improved Human Factors and Comparable PK for Anaphylm Ahe... Aquestive Reports Improved Human Factors and Comparable PK for Anaphylm Ahe... Read Post »
Health TidingsSionna’s SION-719 Fails Phase 2a Sweat Chloride Endpoint in Cystic Fibros... Sionna’s SION-719 Fails Phase 2a Sweat Chloride Endpoint in Cystic Fibros... Read Post »
Clinical TrialsSonelokimab Delivers 42.1% ACR50 Response in Phase 3 Psoriatic Arthritis Tr... Sonelokimab Delivers 42.1% ACR50 Response in Phase 3 Psoriatic Arthritis Tr... Read Post »
Health Tidings Mergers & AcquisitionsSobi enters strategic partnership with Innate Pharma to license lacutamab i... Sobi enters strategic partnership with Innate Pharma to license lacutamab i... Read Post »
Health TidingsNicox Announces NCX 470 NDA Submission in China by Partner Ocumension Nicox Announces NCX 470 NDA Submission in China by Partner Ocumension Read Post »
Clinical TrialsTNX-103 Misses Primary Endpoint, Shows Benefit in More Severe PH-HFpEF TNX-103 Misses Primary Endpoint, Shows Benefit in More Severe PH-HFpEF Read Post »
Health Tidings Mergers & AcquisitionsBeOne, Revolution Medicines Expand RAS(ON) Cancer Collaboration in Asia BeOne, Revolution Medicines Expand RAS(ON) Cancer Collaboration in Asia Read Post »
